Replies to post #100038 on Biotech Values

[DewDiligence]

Since Interferon HCV treatment is likely to be around for at least a few more years this is another bullet in the ability to predict who will respond.

Understood that IP for use of IL-28B as a diagnostic—which is owned by MRK—has commercial value. What I’m asking is whether ZGEN’s IP for treatment of HCV with IL-28A(,B) has commercial value.

p.s. Welcome to the board!